Table II.

Correlation between NY-ESO-1 and LAGE-1 expression and tumor recognition by CAMEL1–11/ORF2- and NY-ESO-1157–165/ORF1-specific CTL

PatientCell LineAg ExpressionHLA-A2aLysis by Specific CTL Clonesb
PCRcWesterndLAU 50 CAMEL/4LAU 156 NY-ESO-1/5
NY-ESO-1LAGE-1NY-ESO-1NY-ESO-1/LAGE-1–P+P–P+P
LAU 50Me 275/CI2++++++++++++++++++++++++
LAU 53Me 312++++++++++++++++++++
LAU 53Me 325+++++++++++++++++++++
LAU 53Me 333+++++++++++++
LAU 289Me 343–/+++++++++++++
LAU 302Me 342++++++++++++++++++++++
LAU 145Me 257++++++++++++++++
LAU 92Me 242.B.1+++++++++++
LAU 119Me 252+++++++++++++++++++
LAU 343T343A+(+)+++++++
LAU 56Me 323++(+)+++++++
LAU 86Me 237+++++++++++++++
LAU 194Me 285.A+++++++++++++++
Me 203Me 290++++++++++++++
LAU 242Me 324+++++++++++
NA8-MEL+++++++
SK-Mel-37+++++++++++++++++++++++
518/IL-2.14+++++++++++++++++++++++++
FM6+++++++++++++++++++++++++
  • a HLA-A2 surface expression was confirmed by flow cytometric analysis.

  • b Tumor lysis by specific CTL clones was assessed in a standard 4-h chromium release assay as detailed in Materials and Methods. Results obtained at E:T ratio of 30 are shown. Percentage of specific lysis is indicated as –, <20%; +, 20–40%; ++, 40–60%, and +++, >60%. –P and +P, Without and with the addition of 1 μM peptide.

  • c NY-ESO-1 and LAGE-1 expression by melanoma lines was assessed by PCR analysis. Scoring was performed as described in the legend to Table I.

  • d Western blotting was performed as described in Materials and Methods with Ab ES121 (detecting NY-ESO-1) and B9.8 (detecting both NY-ESO-1 and LAGE-1). Semiquantitative scoring was made by visual assessment of Western blots similar to that shown in Fig. 4.